Soligenix Inc. Highlights Phase 3 Progress for HyBryte(TM) in CTCL Treatment

Soligenix Inc. (NASDAQ: SNGX) recently shared updates on the clinical development of HyBryte(TM), a potential treatment for cutaneous T-cell lymphoma (CTCL), during an investment webinar. The focus was on an investigator-initiated study at the University of Pennsylvania, led by Dr. Ellen Kim, where interim results showed 75% of the first eight patients completing 18 weeks of treatment experienced more than a 50% reduction in disease severity. HyBryte(TM), a topical therapy activated by visible light, targets early-stage mycosis fungoides, which constitutes nearly 90% of CTCL cases. Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026. This development is significant as it represents a promising advancement in the treatment of CTCL, a rare non-Hodgkin’s lymphoma, addressing a critical unmet medical need. For more details on the clinical development, visit https://ibn.fm/dz7eO.